Oritavancin Use in Patients with Recurrent Bone Infections by Methicillin-Resistant Staphylococcus aureus and Role of Therapeutic Drug Monitoring-Reference-Cited by-同舟云学术

Oritavancin Use in Patients with Recurrent Bone Infections by Methicillin-Resistant Staphylococcus aureus and Role of Therapeutic Drug Monitoring

Published:2024-06-11 Issue: Volume: Page:
ISSN:2732-5326
Container-title:EMJ Microbiology & Infectious Diseases
language:
Short-container-title:EMJ Microbiol Infect Dis

Author:

Bongiovanni Marc¹,Thoueille Paul²,Barda Beatrice¹,Mercier Thomas²,Catia Marzolini³,Cantu Marco⁴,Decosterd Laurent A.⁵

Affiliation:

1. Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland

2. Service and Laboratory of Clinical Pharmacology,Lausanne University Hospital, University of Lausanne, Switzerland

3. Service and Laboratory of Clinical Pharmacology,Lausanne University Hospital, University of Lausanne, Switzerland 3. Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland

4. Istituto di Medicina di Laboratorio EOLAB Ente Ospedaliero Cantonale, Bellinzona, Switzerland

5. Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland; University of Geneva, Switzerland; University of Southern Switzerland, Lugano, Switzerland

Publisher

European Medical Group

Reference5 articles.

1. McKay GA et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2009;6(3):1191-9.

2. Corey GR et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180-90.

3. Corey GR et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254-62.

4. Lupia T et al. Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments. Life (Basel). 2023;13(4):959.

5. Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents 2019;53(4):429-34.